ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
 PMID: 22037848       2012       Antimicrobial agents and chemotherapy
Abstract: Moreover, we induced F18-resistant viruses by in vitro serial passages and found that the mutation L100I appeared to be the dominant contributor to F18 resistance, further suggesting a binding motif different from that of nevirapine and efavirenz.


  Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
 PMID: 22095671       2012       Proteins
Abstract: Moreover, toward the L100I/K103N double mutant, RPVs charge distribution is quite far from optimal.


  Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
 PMID: 22267476       2012       Antiviral therapy
Abstract: NNRTI mutations selected were V179I (5 patients), V179L (1), V179F (2), L100I (1), K103N (2), Y181C (3), K101E (1), K101R (1) and H221Y (1).


  Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
 PMID: 22337292       2012       Journal of medical virology
Abstract: The most prevalent ETR RAMs observed were L100I, V90I, and K101E, with a prevalence of 16.4% (n = 9), 9.1% (n = 5), and 5.5% (n = 3), respectively.


  HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.
 PMID: 22359615       2012       PloS one
Table: L100I


  Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
 PMID: 22384138       2012       PloS one
Result: We also checked population sequences for additional AZT/3TC/NVP-selected resistance mutations like M41L, D67N, K70R, L210W, T215Y/F and K219QE for AZT, K65R for 3TC and L100I, K101P, V106A/M, V108I, Y188C/L/H and G190A for NVP.


  Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.
 PMID: 22592583       2012       Journal of acquired immune deficiency syndromes (1999)
4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM


  Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
 PMID: 22818969       2012       Journal of clinical virology
Abstract: The 11 RAMs not detected by bulk sequencing were A98G (n=2), L100I (n=3), K101E (n=2), V106I (n=3) and E138G (n=1).


  Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents.
 PMID: 22870806       2012       Archives of pharmacal research
Abstract: The results showed that some 2-chloro substituted thiazolylthioacetamide derivatives possessed potent activity against wild type HIV-1 and several key mutant strains (E138K, K103N, L100I) of HIV-1 in MT-4 cells with EC(50) values in micromolar range.


  Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon.
 PMID: 23199801       2012       Journal of the International AIDS Society
Result: Major NNRTIs DRMs were also obtained at positions P225H (n=12), K101E (n=11), Y181C (n=10), G190A (n=7), Y188L (n=6), V90I (n=5), E138A/G (n=5), M230L (n=4), A98G (n=3), H221Y (n=3), L100I (n=3), V179D (n=2), and V106I (n=1).



Browser Board

 Co-occurred Entities




   Filtrator